Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An" or the "Group", HKEX: 2318; SSE: 601318) is pleased to announce Ping An Global Voyager Fund is leading an investment of US$15 Million in Riverain Technologies, a leading provider of clinical artificial intelligence software used to efficiently detect lung disease at its earliest stages. Riverain Technologies markets advanced artificial intelligence imaging software used by leading hospitals around the world. The software significantly improves a clinician's ability to accurately and efficiently detect cancer and other cell anomalies in thoracic CT and X-ray images. The company's suite of patented ClearReadTM software tools are FDA-cleared, deployable in the clinic or in the cloud, and powered by the most advanced artificial intelligence and machine learning methods available to the medical imaging market. Its products are relied upon by leading healthcare institutions, including Duke University, Mayo Clinic, University of Chicago, University of Michigan, and Veterans Affairs hospitals.

H2O.ai, which is on a mission to "democratize" artificial intelligence for not just enterprises, but for "everyone," announced this morning a $72.5 million Series D. This round nearly doubles the amount the company had raised in previous financings combined over its lifetime. Goldman Sachs and the Ping An Global Voyager Fund out of China led the round, which also included participation from existing backers Wells Fargo, NVIDIA GPU Ventures and Nexus Venture Partners. As part of the financing, Jade Mandel, vice president of Goldman Sachs' principal strategic investments group, will be joining H2O.ai's board. The round brings H2O.ai's total raised since it was founded in 2012 to nearly $147 million. Wells Fargo and NVIDIA GPU Ventures led its $40 million Series C in November 2017.